NEW YORK, June 19 - Genomica said Tuesday it had appointed Michael Savage, formerly CEO of Molecular Simulations, to its board of directors.
Savage will replace Arnold Levine, who is joining Genomica's scientific advisory board.
Savage was CEO of Molecular Simulations for eight years before the company was acquired by Pharmacopeia in 1998.
Genomica of Boulder, Colo., develops and markets software products and services, designed to enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process.